The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma
On July 23, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to cobomarsen (MRG-106), for the treatment of T-cell lymphoma.
Cobomarsen is an inhibitor of microRNA-155 (miR-155). Overexpression of miR-155 is associated with poor prognosis in a variety of T-cell lymphomas and several other blood cancers. In 2017, the FDA and the European Medicines Agency (EMA) granted orphan drug designation to cobomarsen for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).
Cobomarsen is currently under investigation in two clinical trials, a phase II trial (NCT03837457) for CTCL and a phase I trial (NCT02580552) for adult T-cell leukemia/lymphoma (ATLL). It has demonstrated promising results in patients with CTCL and ATLL, and it could be potentially used as a broad-based therapy for the treatment of other cancers with elevated levels of miR-155.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content